Bills Target UnitedHealth, CVS, Cigna PBM Control as Premiums Rise 18% Since 2022
Congress is advancing structural remedies against three health conglomerates whose PBM subsidiaries dominate drug distribution and pricing. Evidence links this concentration to faster premium growth and higher patient costs. Outcomes hinge on enforcement details and insurer responses over the next 18-24 months.
The proposed legislation would impose fiduciary duties on PBMs and bar spread pricing, measures already enacted in Arkansas and Ohio with early evidence of 4-7% net price reductions. Insurers argue divestiture would raise administrative costs; independent modeling from the Congressional Budget Office projects modest net savings once behavioral offsets are included. Next steps include Senate HELP Committee markup and potential state attorneys general parallel suits.
FTC: Successful divestiture orders will produce measurable 5-8% net price declines in affected therapeutic classes within 24 months of implementation.
Sources (3)
- [1]NYT Coverage of Breakup Legislation(https://www.nytimes.com/2026/07/08/business/health-insurance-cvs-unitedhealth-breakup.html)
- [2]JAMA Network Open Analysis of PBM Vertical Integration(https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823456)
- [3]Health Affairs Study on Regional PBM Concentration(https://www.healthaffairs.org/doi/10.1377/hlthaff.2024.01234)